⚡️🇺🇸#INCY #отчетность
Incyte - Q1 Non-GAAP EPS of $0.67 beats by $0.03; GAAP EPS of $0.24 misses by $0.17.

Revenue of $605M (+6.4% Y/Y) misses by $55.72M.
Jakafi (ruxolitinib) revenues of $466M (+1% Y/Y) vs. consensus of $516.5M.

#прогноз Reaffirms full year guidance of Jakafi (ruxolitinib) revenues of $2.125-$2.20 billion.

⚠️🇺🇸#INCY
FDA отказалась одобрить заявку Incyte на препарат retifanlimab

💥🇺🇸#LLY #INCY
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen